Elsevier

Autoimmunity Reviews

Volume 1, Issue 6, December 2002, Pages 313-320
Autoimmunity Reviews

Chemokines in autoimmunity: from pathology to therapeutics

https://doi.org/10.1016/S1568-9972(02)00085-XGet rights and content

Abstract

Leukocyte recruitment, accumulation, and activation have been both a unifying and enigmatic feature of a variety of autoimmune pathologies. While these processes were not well-known for decades, recent scientific discoveries have underscored the importance of specific chemokines in the evolution of autoimmunity. This has been supported by in vivo data from clinical studies and animal model experiments. Although chemokines are an attractive target for drug development, there are hurdles that need to be cleared. Nonetheless, the quest to understand chemokine biology and develop effective therapies continues to capture the imagination of scientists in academia and pharma alike.

Section snippets

Introduction to the chemokine system

Chemokines are a large family of small secreted proteins (8–15 kDa) that control the trafficking of specific leukocyte subpopulations both in physiological and pathological processes. In the last few years, it has been demonstrated that these mediators play a role in embryonic development, hematopoiesis, angiogenesis, host defence, inflammation, immunity, AIDS and cancer [1], [2], [3].

According to the arrangement of the cysteine residues near the amino terminus, chemokines are classified into

Inflammatory and lymphoid chemokines

From a functional point of view, chemokines can be broadly classified into two classes: inflammatory and lymphoid. This distinction is not absolute, and some members can be ascribed to both subclasses. The inflammatory chemokines are induced by pathogens and proinflammatory stimuli in both resident tissue cells and leukocytes [1], [4], [5]. Their receptors are expressed on phagocytes such as neutrophils, eosinophils and monocytes, in immature dendritic cells (DC) and in some stages of T cell

The complexity of the chemokine system

The existence of approximately 50 ligands and 18 receptors indicates that the relationship between them are far from being of a single ligand/receptor pair interaction. Redundancy and promiscuity of binding are well-known features of the inflammatory chemokines, with a single chemokine binding to different receptors and a receptor binding to different chemokines. What is the meaning of the redundancy and whether it really operates in vivo is a matter of debate.

The comparison of the properties

Chemokines in autoimmune diseases

The migration and accumulation of leukocytes in the target organs are a critical step in the pathogenesis of autoimmune diseases [15]. The role of chemokines in autoimmunity is based on different lines of evidence provided by studies from humans and animal models.

Chemokines as therapeutic targets

The fact that chemokines act through GPCR stimulated pharmaceutical companies to the search for small molecule receptor antagonists, given the historical success of these targets. The first efforts were mainly focused on CCR1 and CCR2 antagonists as targets for autoimmune diseases, CXCR2 antagonists for neutrophil-mediated disorders, and CCR5 and CXCR4 antagonists for AIDS. Small molecule antagonists with nanomolar potency against several chemokine receptors have been reported both in the

Immune chemokines as therapeutic targets?

Recent evidences suggest that lymphoid chemokines would make interesting targets, although their role in homeosthasis could raise some doubts about the potential toxicity of this approach.

The pairs CCR7/CCL21, CXCR5/CXCL13 and CXCR4/CXCL12 are the main lymphoid ligand/receptor pairs. Perturbation in the expression of CCL21 has been described to alter susceptibility to autoimmunity in a model of experimental diabetes in mice [32]. The transgenic expression of CCL21 in the pancreas induces the

Summary

The field of chemokines is moving fast. Only a decade ago, the role of inflammatory chemokines in innate immunity and acute inflammation was established. In the last 5 years, the studies on chemokines have helped to understand their role in the orchestation of lymphocyte migration during immune responses. In the future, we will learn more about the role of specific chemokines in autoimmune diseases, as current knowledge suggests that blocking chemokine/receptor interaction is a suitable

References (39)

  • K.E. McGrath et al.

    Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4

    Dev. Biol.

    (1999)
  • D. Rossi et al.

    The biology of chemokines and their receptors

    Annu. Rev. Immunol.

    (2000)
  • B. Homey et al.

    Chemokines: agents for the immunotherapy of cancer?

    Nature Rev. Immunol.

    (2002)
  • M. Baggiolini

    Chemokines in pathology and medicine

    J. Intern. Med.

    (2001)
  • P.M. Murphy et al.

    International union of pharmacology. XXII. Nomenclature for chemokine receptors

    Pharmacol. Rev.

    (2000)
  • I.A. Khan et al.

    Mice lacking the chemokine receptor CCR1 show increased susceptibility to Toxoplasma gondii infection

    J. Immunol.

    (2001)
  • B.C. Chiu et al.

    Chemokine responses in schistosomal antigen-elicited granuloma formation

    Parasite Immunol.

    (2002)
  • G. Muller et al.

    Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors

    J. Leukoc. Biol.

    (2002)
  • B. Moser et al.

    Lymphocte traffic control by chemokines

    Nature Immunol.

    (2001)
  • Cited by (38)

    • Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis

      2020, International Immunopharmacology
      Citation Excerpt :

      The potent CCR5 antagonists have already been developed as entry inhibitors of HIV-1[27] to prevent the development of neuroAIDS. CCR5 is capable of binding to a group of ligands, such as CCL3, CCL4, and CCL5 [28], participating in inflammatory responses [29]. Increased CCL5 levels have been reported in patients with rheumatoid arthritis (RA), and positive patients who are responder to methotrexate have a lower level of CCL5 in their serum samples [30,31].

    • The thymus in autoimmune Myasthenia Gravis: Paradigm for a tertiary lymphoid organ

      2013, Revue Neurologique
      Citation Excerpt :

      Other chemokines such as CCL19 and CXCL12 were also shown to be implicated in leukocyte accumulation, while being less involved in tissue organization (Luther et al., 2002). It is therefore not surprising that chemokines, especially those contributing to cell recruitment, are often overrepresented in the inflammatory tissue of autoimmune diseases (Kunkel and Godessart, 2002) (Table 2). In the hyperplastic MG thymus, the dysregulation of several chemokines has been identified: CXCL12 – known for its effect on GC formation and lymphocyte homing – is expressed on HEVs in the MG thymus, from where it may regulate the infiltration of cells that express the CXCL12 receptor CXCR4 (Weiss et al., 2013).

    • Increasing CCL5/CCR5 on CD4<sup>+</sup> T cells in peripheral blood of oral lichen planus

      2013, Cytokine
      Citation Excerpt :

      It is still unknown whether any other factors contribute to this Th1-dominated immune response, especially the chemokines in OLP. Chemokines are chemotactic cytokines, which can be divided into homeostatic chemokines and inflammatory chemokines by functions [9,10]. ( C–C motif) ligand 5 (CCL5), also known as RANTES (regulated upon activation normal T-cell expressed and secreted) is an inflammatory chemokine with the function of recruiting leukocytes and transferring them to the infected areas or damage tissues [11,12].

    • Real-Time Polymerase Chain Reaction

      2009, Molecular Diagnostics: Second Edition
    • CCL2 DNA vaccine to treat renal disease

      2009, International Journal of Biochemistry and Cell Biology
    View all citing articles on Scopus
    View full text